Form 4: Akero Therapeutics Chief Scientific Officer Sells Shares to Cover Tax Obligations

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, sold 2,358 shares of common stock for approximately $53.996 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO), reported a sale of common stock.
• The transaction occurred on June 10, 2025.
• A total of 2,358 shares were sold at a weighted-average price of $53.996 per share, with prices ranging from $53.337 to $54.00.
• This sale was a "sell-to-cover" transaction, executed automatically to satisfy tax withholding obligations arising from the vesting of restricted stock units.
• Following this transaction, Timothy Rolph beneficially owns 167,363 shares of Akero Therapeutics common stock.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is a routine, non-discretionary sale for tax purposes, which is generally not a negative signal. The company has a clear policy for such sales.

Positives

• The sale was a non-discretionary "sell-to-cover" transaction, indicating it was for tax withholding purposes rather than a reflection of management's view on the company's future performance.
• The company has an established "sell-to-cover" policy, which provides a clear mechanism for executives to manage tax liabilities from equity compensation.

Negatives

• The transaction resulted in a reduction of the Chief Scientific Officer's direct beneficial ownership by 2,358 shares.

Future Outlook

N/A. This filing does not contain forward-looking statements or guidance.

Management Comments

• The sale was automatic and not at the discretion of the Reporting Person, executed to cover tax withholding obligations in connection with the vesting of restricted stock units, as per the Issuer's 'sell-to-cover' policy.

Industry Context

This is a routine insider transaction common across all industries, particularly for executives receiving equity compensation. It does not reflect specific industry trends but rather standard corporate compensation and tax practices.

Comparison to Industry Standards

• This type of 'sell-to-cover' transaction is a common and standard practice for executives in publicly traded companies across various sectors, including biotechnology, to manage tax liabilities arising from equity compensation vesting.
• It is not indicative of a discretionary sale based on company performance or outlook, unlike open market sales. No specific comparable companies or projects are relevant for this type of routine transaction.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but as a non-discretionary transaction for tax purposes, it typically does not signal a change in management's confidence in the company.
• Employees: The transaction relates to equity compensation, which is a common component of executive compensation packages.

Next Steps

• N/A. This filing reports a past transaction and does not outline future actions or milestones.

Key Dates

Recommendation

Keywords

Akero Therapeutics, AKRO, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Chief Scientific Officer, Timothy Rolph, Equity Compensation